PAX5 and hepatocellular carcinoma: Higher titers of autoantibodies against 128 TAAs were observed in HCC patients than those in NCs (AUC > 0.5, p < 0.05), among which 4 targets (GNA11, PTCH1, PAX5, SRSF2) were screened by logistic regression with a combined AUC of 0.825.